Navigation Links
Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced data from two preclinical studies, one identifying a functional biomarker for its novel histone deacetylase (HDAC) inhibitor and another demonstrating preclinical anti-tumor activity with its Bruton's tyrosine kinase (BTK) inhibitor compounds. The data were presented at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held this week in Los Angeles.

Results of an in vitro study (Abstract #1966) demonstrate that Pharmacyclics' HDAC inhibitor, PCI-24781 inhibits homologous recombination, a cellular mechanism of DNA repair, by both down-regulating RAD51 gene expression, and by affecting the ability of the cell to form RAD51 foci at the site of the lesion. The RAD51 gene provides instructions for making a protein that is essential for the repair of damaged DNA. These data suggest that PCI- 24781 could be used successfully in combination with other cancer therapies that generate lesions repaired by homologous recombination, such as gamma- irradiation, cisplatin, and oxaliplatin, and show the usefulness of using RAD51, an enzyme, as a biomarker to predict clinical efficacy. Researchers observed that PCI-24781-treated cells are more sensitive to DNA damaging cancer agents, suggesting that it may act in part by inhibiting DNA repair. PCI-24781 is currently in Phase 1 clinical trials evaluating its safety and effectiveness in both solid and hematological malignancies.

"Not only have we further elucidated the mechanism by which our HDAC inhibitor may kill cancer cells, we have also identified a biomarker that may predict its efficacy in cancer patients," stated Richard A. Miller, M.D., president and CEO of Pharmacyclics. "We have filed patents based on this new information, and are moving this promising compound forward in clinical trials incorporating use of this bioma
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
8. NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking
9. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
Post Your Comments:
(Date:5/16/2008)...s Potential Biomarkers -- for Lung Cancer Diagnosi...With Cancer of Unknown Primary ...fy Cancer Types With High Sensitivity and, Speci...ment of Cancer Results of microRNA Signature to I...racy Exceeding 90% and Specificity of 99%, REHOVO...
(Date:5/15/2008)...KE, N.J., May 15 /- Eisai Corporation...m 16 clinical data abstracts about,compounds in th...nd,preclinical oncology research have been accepte...he American Society of Clinical Oncology (ASCO),t...., A wide variety of abstracts on Eisai marketed ...
(Date:5/15/2008)...Presented at ASCO Showed Acceptable Tolerability P...and 4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /P... agent eribulin mesylate (E7389) demonstrated acti...ith locally advanced or metastatic,breast cancer, ...inical,trial. The study also suggests that eribuli...
(Date:5/15/2008)... N.J., May 15 /- Sanofi-ave... that findings from the,landmark ATHENA study show...r the treatment of patients with atrial fibrillati...vascular hospitalizations or death from any,cause ... meeting the study,primary endpoint. The ATHENA re...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 1Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 1Precancerous Breast Lesions Cause Unnecessary Worry 11716 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 3Precancerous Breast Lesions Cause Unnecessary Worry 11716 4Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 1Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 2Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 3Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 1Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 2
(Date:5/16/2008)...edicine is in a precipitous decline, David C. Dale...hysicians (ACP), today joined with leading repres...ll for comprehensive reforms to attract, recruit a...e physicians. , During a panel discussion of th...Dale and other panelists spoke about the challenge...
(Date:5/16/2008)...wswire/- "Huh, what did you,say?" is a phrase bein...hildren. More than 30 million Americans, that is 1...nd the numbers are growing at a dramatic rate.,Thi...me form of hearing,loss. An effort to bring more a...at led Kathlyn Maguire, who has profound hearing l...
(Date:5/16/2008)...Million for Life-threatening,Disease, BETHESDA, M...early,every state will raise funds for cystic fibr...ting in GREAT STRIDES, the largest national CF,fun... today., May is National Cystic Fibrosis Awarenes...etic disease that causes fatal lung infections and...
(Date:5/16/2008)...10,000 Sensual O Condom Packs Donation Marks the ... LOS ANGELES, May 16 /PRNewswire/ -- On Saturday, ...wn best for his hit song "Everybody in the Club,Ge...Institute (UHI) with,10,000 Sensual O Vibrating Co...ng made to promote the launch of the Association f...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Everybody in the Club Scream O! 2
...eghalaya so far this year, state Health minister E... to a calling attention notice, Marak said 11 deat...South Garo, six from East Garo Hills, nine died in...hasi and Ri-Bhoi district reported three deaths. T...
...r C. Divakaran Wednesday confirmed that pig fever ...igs at a private farminwayanad//. This is believed...he country. "Pig fever was ascribed to the death ...inary Research Institute in Uttar Pradesh after sa...
...ause heat is capable of relieving pain, say resear... use of DNA technology//, scientists were able to ...ells. When the heat is on, it has a pain relievin...s of heat for pain relief on par with a pain kille...
...exander Downer has sanctioned $17 million to take ...on of HIV-AIDS//, tuberculosis and malaria. To quo...re than half a million people to be treated with a...an $1.4 million people to be treated for tuberculo...
Other Medicine News:
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens.
...ade; hydrophilic acrylic IOL is the newest advance...e patient and surgeon in mind. Its unique one-piec...rosslinked with PMMA haptics to provide superb con...e and biocompatibility. The high memory lathe-cut ...
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
TRIPODE Hydrophilic Acrylic Lens.
Medicine Products: